Key statistics
On Thursday, Eckert & Ziegler SE (EUZX:GER) closed at 43.76, -12.57% below its 52-week high of 50.05, set on Jul 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 41.72 |
---|---|
High | 44.48 |
Low | 41.72 |
Bid | 43.68 |
Offer | 43.84 |
Previous close | 41.56 |
Average volume | 16.63k |
---|---|
Shares outstanding | 21.17m |
Free float | 14.53m |
P/E (TTM) | 22.19 |
Market cap | 879.91m EUR |
EPS (TTM) | 1.87 EUR |
Annual div (ADY) | 0.05 EUR |
---|---|
Annual div yield (ADY) | 0.12% |
Div ex-date | Jun 27 2024 |
Div pay-date | Jul 01 2024 |
Data delayed at least 15 minutes, as of Sep 19 2024 16:24 BST.
More ▼
- EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
- EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
- EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
- EQS-News: Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
- EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
- EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
- EQS-News: Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
More ▼